We Already Legalized "Designer Babies" Decades Ago — We Just Didn't Call Them That
Summary
In June 2026, Columbia University's Dieter Egli research team published a bioRxiv preprint documenting the successful application of base editing to human embryos, achieving precise correction of disease-causing genetic variants including PCSK9 and HBG1/2, with some embryos reaching 100% editing efficiency — reigniting the global designer baby debate that had largely quieted since the 2018 He Jiankui scandal. Unlike conventional CRISPR-Cas9, which physically severs both DNA strands and introduces unpredictable repair artifacts, base editing chemically converts a single nucleotide without cutting the helix, representing a qualitative leap in precision that earlier human germline editing attempts lacked entirely. Despite the technical advance, mosaicism — the uneven distribution of edits across embryonic cells — remains unresolved, and the involvement of consumer genomics company Nucleus Genomics as a funder raises legitimate questions about whether the research's ultimate destination is therapy or commercial genetic enhancement. The American Society of Gene and Cell Therapy and the International Society for Cell and Gene Therapy responded with a joint 10-year moratorium on germline editing, a move that is symbolically significant but carries zero legal enforcement power, extending a familiar pattern of paper prohibitions that failed to stop He Jiankui eight years ago. If this technology commercializes before robust international regulation is in place, the most likely outcome is access gated entirely by wealth — embedding health inequality at the DNA level and initiating what would be the first biologically encoded class divide in human history.
Key Points
The Technical Leap: Base Editing vs. CRISPR and What It Actually Changes
The base editing approach used by Dieter Egli's Columbia team represents a genuine generational shift in the precision of human genetic manipulation. Conventional CRISPR-Cas9 works by deploying guide RNA to locate a target DNA sequence and then using the Cas9 protein to physically sever both strands of the double helix — a molecular cut-and-paste that inevitably generates a cellular repair response, and that repair process frequently introduces unintended insertions or deletions at the break site. Base editing eliminates the cut entirely: a deaminase enzyme chemically converts one nucleotide — cytosine to thymine in CBE systems, adenine to guanine in ABE systems — and achieves the desired genetic change without breaking the DNA backbone. In Egli's experiment, cytosine base editors targeted the PCSK9 variant responsible for familial hypercholesterolemia, while adenine base editors corrected HBG1/2 variants implicated in sickle cell disease, with some embryos achieving 100% efficiency across all sampled cells. The practical implication is that what was previously a conceptual possibility — correcting a disease variant before implantation, consistently, safely, and completely — now has meaningful experimental support. This doesn't mean the technology is ready for clinical application, but it does mean the scientific case for "it can't be done safely" has become significantly harder to sustain. I regard this as the point at which the debate transitions from "should we research this?" to "what specific conditions, if any, would permit its use?"
The Moratorium Problem: Why Professional Society Statements Are Not Regulation
The joint 10-year moratorium on germline editing issued by ASGCT and ISCT is the kind of statement that sounds decisive and accomplishes very little, and it's worth being precise about why. A moratorium issued by a professional society carries weight only for researchers who are members of that society and whose careers are invested in good standing with that community. It has zero effect on researchers in non-member institutions, zero effect on researchers in countries where those societies have no influence, and zero effect on commercial operators who are not bound by scientific community norms. The closest historical analogy is the 1975 Asilomar Conference on recombinant DNA, where scientists voluntarily paused research and drafted safety guidelines — but the path from voluntary moratorium to actual institutional regulation took years, and research didn't actually stop during that period. He Jiankui's 2018 experiment is a far more recent case study: he conducted his work while multiple moratoriums from scientific bodies were in effect, was prosecuted under Chinese domestic law rather than any international framework, and served a three-year prison sentence that produced no durable change in the international regulatory landscape. I believe the ASGCT/ISCT statement reflects genuine concern from responsible scientists, and I respect that — but mistaking it for regulation would be a serious error. The gap between "scientists said not to" and "there are meaningful consequences if you do" is precisely where the real risk lives.
The Nucleus Genomics Problem: Commercial Interests in Therapeutic Research
The presence of Nucleus Genomics as a funder of this research is a detail that deserves more attention than most coverage has given it, because it speaks directly to where this technology is actually headed. Nucleus Genomics is a direct-to-consumer genetic testing company — its business model is selling genomic information directly to individuals without a physician intermediary. That's a legitimate business, and the DTC genomics space has produced real consumer value. But here's the commercial logic that concerns me: the DTC genomics market is maturing rapidly, with consolidation underway and core sequencing costs approaching commodity pricing. Companies in this space are actively looking for their next high-margin product. High-value, customized genetic services sold to affluent consumers who want to optimize their children's health outcomes are exactly what the DTC model was built to deliver. Embryo editing is not the kind of foundational research that typically attracts commercial biotech investment — it attracts commercial investment when the funder sees a future product line. When NIH or the Wellcome Trust funds this research, the implied destination is a regulated therapy with broad access ambitions. When a consumer genomics company funds it, the implied destination is a premium consumer service. That is not a conspiracy — it's straightforward capital allocation logic, and the DTC genomics industry's progression from ancestry testing to health risk reporting to reproductive planning services follows a predictable sequence in which embryo editing is the obvious next chapter.
The PGT-M Paradox: Society's Existing Double Standard on Genetic Selection
One of the most intellectually uncomfortable aspects of the embryo editing debate is the near-total silence about the practice it is implicitly compared to in virtually every ethical argument: preimplantation genetic testing for monogenic disorders, or PGT-M. This is an established, legal, and widely practiced medical procedure in which embryos produced through IVF are biopsied and genetically screened, and those carrying disease-causing variants are identified and typically not transferred — meaning they are discarded. This happens right now, in fertility clinics across the U.S., Europe, and dozens of other countries, for hundreds of genetic conditions, and has been happening for decades. The ethical objection most commonly raised against embryo editing is that it constitutes inappropriate human interference with the genome. Yet PGT-M already selects against specific genetic sequences — it just does so by discarding the embryo rather than correcting the variant. The argument that PGT-M is ethically permissible while embryo editing is not requires holding simultaneously that destroying an embryo with a disease variant is acceptable, but correcting that variant in the same embryo is forbidden. I am not saying embryo editing should automatically be permitted. I am saying that ethical frameworks which accommodate PGT-M while prohibiting embryo editing need to articulate their reasoning far more carefully than they typically do. The reversal matters: editing might actually save embryos that current screening destroys.
The Genetic Class Divide: Why This Inequality Is Different From All Others
Every era has its form of inherited advantage — land in feudal systems, capital in industrial economies, social networks in the information age. What embryo editing threatens to introduce is something qualitatively different: biological advantage encoded directly into the germline, propagating automatically across generations without any additional economic investment. Consider the compounding logic carefully. Families in the top global income percentiles gain access to embryo editing first, simply because they can afford the initial price point. Their children are born with disease variants corrected and, conceivably in later years, with other traits optimized. Those children are healthier, more productive, statistically likely to earn more, and when they have children, those children carry the same genetic advantages without any additional procedure or cost. The advantage compounds biologically in a way that no economic advantage can. Economic wealth can be taxed, redistributed, lost in a market crash, or dissipated by poor decisions. Germline genetic changes, by definition, cannot be taxed, redistributed, or reversed by any policy mechanism currently available to human societies. World Inequality Report data shows the top 10% of earners currently control approximately 76% of global wealth. Adding a biological multiplier to that existing imbalance produces something for which we genuinely don't yet have adequate moral vocabulary — a form of stratification where starting conditions differ at the cellular level, and where no amount of social policy can close the gap once it is established.
Positive & Negative Analysis
Positive Aspects
- The Genuine Medical Promise: Eliminating Inherited Disease Before Birth
The case for pursuing base editing in human embryos under appropriate conditions begins with a simple but weighty fact: single-gene disorders collectively cause an enormous amount of preventable suffering worldwide. Sickle cell disease affects approximately 300,000 newborns annually, the great majority in sub-Saharan Africa, where it remains a leading cause of under-five mortality. Cystic fibrosis affects roughly 1 in 2,500 to 3,500 births in populations of European descent, with a median survival age that, despite recent advances like Trikafta, still falls around 40 to 50 years. The PCSK9 variant targeted in Egli's research causes familial hypercholesterolemia, affecting roughly 1 in 300 people globally, which dramatically elevates cardiovascular mortality risk if untreated. Embryo-stage correction would change the fundamental terms of these problems: instead of treating a person who has been living with a disease for decades, the disease is prevented from ever arising — with every cell in the child's body carrying the corrected sequence from the moment of fertilization. Current somatic gene therapies like Casgevy, priced at approximately $2.2 million per treatment, require intensive conditioning regimens that pose serious risks to patients who are already ill, and can only address damage after it has begun. I believe the medical case for this technology, developed responsibly and accessed equitably, is genuinely strong — and dismissing it entirely in the name of precaution ignores real people with real inherited diseases who stand to benefit enormously.
- The Safety Advantage: Why Base Editing Is Categorically Different From Prior Tools
The safety profile of base editing relative to conventional CRISPR-Cas9 is not just incrementally better — it is structurally different in ways that address the most serious concerns about clinical application. A 2020 paper in Nature Biotechnology documented large deletions — sometimes extending kilobases — occurring at CRISPR-Cas9 target sites, raising serious concerns about the potential for oncogenic effects in edited cells. These large structural rearrangements are a direct consequence of the DNA double-strand break and the cell's error-prone non-homologous end joining repair mechanism. Base editing avoids this mechanism entirely: because no double-strand break is induced, the risk profile for large deletions and chromosomal translocations is fundamentally reduced, not just marginally improved. Egli's team reported off-target base editing frequencies meaningfully lower than those typically observed with Cas9-based approaches. Base editing does have its own specific safety concerns — bystander edits at adjacent bases are a known issue in some CBE and ABE systems — but the overall risk profile is clearly superior to prior-generation tools. This matters practically: the safety evidence required to support a clinical application of base editing is more achievable than it was for first-generation CRISPR. Treating all forms of genome editing as equally risky would be factually incorrect and would make it harder to have a precise conversation about what oversight is actually proportionate to the actual risks.
- Surpassing the Fundamental Limits of Somatic Gene Therapy
The approved somatic gene therapies for conditions like sickle cell disease represent extraordinary scientific achievement and real therapeutic benefit for patients who receive them. But they carry fundamental limitations that embryo editing could theoretically bypass entirely. Casgevy requires patients to undergo myeloablative conditioning — essentially destroying existing bone marrow to make room for edited stem cells — a medically intensive process that poses serious risks including infection, infertility, and organ damage. The therapy applies only to blood-forming cells; it cannot reverse damage already done to organs affected by years of disease prior to treatment. It can only be administered after the patient is old enough to tolerate the conditioning regimen. And the $2.2 million price point puts it categorically out of reach for the vast majority of patients with sickle cell disease, who live primarily in low-income countries without the healthcare infrastructure or financing mechanisms to access such therapies. Embryo editing would produce a child who never develops the disease in the first place — no conditioning regimen, no organ damage from prior illness, no delayed intervention. Over time, as base editing procedures become more routine, their economic cost would likely fall well below that of postnatal therapies, which involve far greater manufacturing complexity. For millions of people in low-and-middle-income countries who will never access Casgevy, a preventive embryo-stage approach may ultimately represent the more realistic path to eliminating these diseases at population scale.
- The Ethical Reversal: Does Editing Save More Embryos Than Screening Discards?
This argument is rarely made in mainstream bioethics discussions, possibly because it is genuinely uncomfortable for advocates on both sides. Standard IVF practice in conjunction with PGT-M routinely produces more embryos than will be transferred, and those carrying disease variants are typically discarded. Average IVF cycles in the U.S. generate between eight and twelve embryos, and PGT-M screening often results in the discard of a substantial fraction of those, sometimes the majority, depending on the condition and the patient's genetic profile. From a perspective that emphasizes the moral status of embryos — as many religious traditions do — this existing reality is already quite ethically troubling. Now consider the reversal: if embryo editing could correct disease variants in embryos that would otherwise be discarded, it would not be increasing embryo destruction — it would be reducing it. The same religious and ethical traditions that oppose embryo editing most forcefully also tend to oppose embryo destruction most forcefully. A technology that converted embryos previously deemed "defective" into viable ones, rather than discarding them, is arguably more consistent with those values than PGT-M's current practice of selection and elimination. Some Catholic bioethicists have begun to articulate cautious versions of this argument. I am not presenting this as a definitive resolution of the ethical problem — the concerns about consent and germline modification remain serious. But the framing of embryo editing as categorically anti-life ignores the possibility that it might be precisely the opposite, depending on how it is applied.
Concerns
- Genetic Class Stratification and Irreversible Intergenerational Inequality
The concern about genetic class stratification is not a distant hypothetical — it is the predictable downstream consequence of introducing a high-value, high-cost technology into a world of radical wealth inequality. Plausible initial cost estimates for a clinical embryo editing procedure run from $500,000 to over $1 million, placing it in the same economic universe as certain luxury real estate — accessible to households in the top one to five percent of global income distribution. At that price point, the technology functions not as medicine but as a privilege, and one that transmits its benefits automatically and permanently across generations. Unlike economic wealth, which can be redistributed through taxation, dissipated through bad decisions, or disrupted by market change, germline genetic advantages propagate without any further investment. A child born with optimized disease resistance will, on average, be healthier, more productive, and wealthier than counterparts without those advantages — and will pass those advantages to their own children without additional cost or effort. The World Inequality Report documents that the top 10% of global earners already control 76% of total global wealth. Layering a biological advantage system on top of that existing extreme concentration creates something with no historical precedent: a class divide where the differentiation is not just economic but biological, where baseline physical capabilities of different social classes differ at the cellular level, and where no redistribution mechanism in our current political toolkit can close the gap once it is established.
- Mosaicism: The Unresolved Technical Barrier to Safe Clinical Application
Even in Egli's high-efficiency experiment, results were not uniform across all embryos or all cells within embryos. Mosaicism — the condition in which different cells within the same organism carry different genetic sequences — was observed in portions of the dataset. This is a deeply serious problem for clinical application that is worth being precise about, because its implications are not intuitive at first glance. An embryo with 100% editing efficiency in sampled cells could still be mosaic in tissues that weren't sampled, particularly given that biopsying an early embryo is itself a sampling procedure with inherent limitations. If a mosaic embryo is implanted and develops to term, the resulting child might carry the corrected sequence in some tissues while other tissues retain the original disease variant. The health consequences of this kind of inter-tissue genetic mosaicism are genuinely unpredictable with our current knowledge. Autoimmune reactions, developmental anomalies, and differential disease expression across organs are all plausible consequences that cannot be ruled out without long-term human developmental data that simply does not yet exist. The only way to generate that data is to implant edited embryos and track children over decades — which is itself the intervention that remains ethically prohibited. This logical catch-22 means we cannot prove safety without clinical data, and should not generate clinical data without proof of safety. I think mosaicism is a more fundamental barrier to responsible clinical application than the optimistic framing of Egli's results suggests.
- The Slippery Slope Is Not a Fallacy — It's a Commercial Logic
In ethics debates, invoking the slippery slope is often treated as intellectually lazy shorthand. In the context of embryo editing, it is actually a precise description of a commercial and regulatory dynamic we should expect to unfold rather than fear as a remote possibility. The problem begins with the genuine ambiguity inherent in the therapy-versus-enhancement distinction. Correcting the PCSK9 variant to prevent familial hypercholesterolemia is clearly therapeutic. But the PCSK9 protein is involved in cholesterol metabolism more broadly, and a loss-of-function edit that eliminates disease risk also produces cardiovascular benefit in people who don't carry the disease variant — is that therapy or enhancement? The myostatin gene regulates muscle growth, and loss-of-function variants are associated with exceptional muscular development. Editing embryos to introduce such variants would not treat disease — it would optimize physical performance. Where does the regulatory line go, and who draws it? Once the clinical infrastructure for embryo editing is established for therapeutic purposes, redirecting it toward enhancement is primarily a business decision, not a technical one. The history of reproductive medicine in the U.S. — where embryo sex selection is legal and practiced without therapeutic rationale — suggests that the boundary between permitted and prohibited genetic selection will ultimately be drawn by market demand as much as by ethical consensus. Once the slope is established, finding a stable stopping point has historically proven very difficult.
- Embryo Editing Tourism and the Regulatory Arbitrage Problem
The scenario in which unregulated embryo editing services emerge in jurisdictions with minimal oversight is not speculative — it is the predictable extension of a well-documented pattern in global healthcare. Stem cell tourism established itself as a multi-hundred-million-dollar industry serving patients from wealthy countries who sought unproven treatments in Panama, Ukraine, Thailand, and other jurisdictions with limited regulatory capacity. For embryo editing, the commercial incentives are substantially stronger than they were for stem cell treatments, because the product — a child with corrected or enhanced genetics — has lifetime value rather than temporary symptom relief. Initial pricing in the hundreds of thousands of dollars, potentially declining to $100,000 to $200,000 within five to seven years as technical costs fall, puts this within reach of a substantial global affluent population. Clinics in jurisdictions without HFEA-equivalent oversight would face no requirement for the safety monitoring, long-term follow-up, or outcome reporting that responsible clinical development requires. Children born from unmonitored procedures would have no registries, no standardized follow-up protocols, and no mechanism for identifying systemic safety signals across cases. By the time regulatory bodies in wealthy countries identified a safety problem, thousands of procedures might already have occurred with no reliable data on outcomes. I believe the timeline for embryo editing tourism to emerge is closer to five years than twenty, and that once that market exists, shutting it down will be extraordinarily difficult.
- Consent, Autonomy, and the Permanent Modification of Future Generations
The fundamental ethical problem with germline editing — the one that is genuinely difficult to argue around — is that the person most directly affected by the decision has no capacity to consent to it. Medical ethics since the Nuremberg Code has been built on the foundational principle that competent individuals have the right to make informed decisions about their own care, and that procedures with significant risks and uncertain long-term outcomes should not be performed on people who cannot meaningfully agree to them. Somatic gene therapies can be consented to by adult patients who understand the risks and have the right to refuse. Embryo editing cannot. The decision is made before the person exists, by parties — the parents and the medical team — whose interests may not align with those of the resulting child. Moreover, germline editing transmits the modification to every subsequent generation, indefinitely. Parents making a decision about one embryo are making a decision that will affect their grandchildren, great-grandchildren, and all subsequent descendants — none of whom can consent, and some of whom might, if they could be asked, prefer to receive the unedited genome. As genetic technology advances, future people may have options for modifying their own genomes that are far safer and more reversible than germline editing. A person who inherits a germline edit may face constraints on future personal choices that their unedited counterpart would not have. The autonomy concern is not resolvable by improving the technology or reducing commercial pressure — it is structural, and I think it requires genuinely independent ethical analysis before clinical application proceeds.
Outlook
In the immediate term — the next six months — the most predictable development is the paper's journey through formal peer review and eventual publication in a top journal. Egli's preprint was posted to bioRxiv on June 1, 2026, without yet clearing peer review. Once it publishes in Nature or Science, public conversation will scale dramatically relative to what we've seen so far. In the U.S., FDA regulations currently prohibit clinical trials of human germline editing through a rider on the annual Consolidated Appropriations Act. Critically, this is not permanent law — it gets renewed annually and could theoretically be reversed or permanently codified in either direction. I give roughly 70% odds that formal publication of Egli's results triggers congressional hearings, with advocates on both sides pushing hard for different legislative outcomes. This will be the most important near-term regulatory moment for this technology in the United States.
In the UK, the Human Fertilisation and Embryology Authority operates independently of the Oviedo Convention, which the UK never signed. Depending on how HFEA interprets this research, a scenario in which the UK becomes the first jurisdiction to authorize tightly controlled germline research trials — not clinical application, but supervised laboratory research — is not impossible. That would represent a significant geopolitical moment and would put enormous pressure on other European regulators to define their positions more precisely than they have so far. Europe's internal division between Oviedo Convention signatories and non-signatories means there is no unified European stance, and this vacuum creates room for regulatory divergence that commercial interests will be watching closely.
One additional short-term variable deserves attention: China. After He Jiankui, China toughened criminal penalties for germline editing in 2019. But it simultaneously pursues the world's most aggressive program of somatic gene therapy clinical trials. As of 2026, China has active CRISPR-based trials for blood disorders, cancer, and other conditions numbering in the dozens. The technical infrastructure required for germline editing isn't far removed from this somatic work — it's adjacent, not distant. I estimate roughly a 40% probability that informal germline research is already underway below the threshold of regulatory visibility. He Jiankui himself was released from prison in 2024 after serving his three-year sentence, and where his expertise went is not publicly documented. That is not a trivial concern.
In the medium term — six months to two years out — the commercial landscape will begin to reshape significantly. The global gene therapy market was estimated at approximately $13 billion in 2025, projected to reach $26 billion by 2028. Egli's results function as a proof of concept that will attract substantial venture capital interest in germline editing pipelines. I expect at least three to five additional biotech startups to quietly begin constructing germline editing programs alongside existing players. The pivotal actors to watch are Beam Therapeutics — which holds key base editing patents and whose roughly $4.5 billion market cap could double or triple if a clinical pathway opens — and the Broad Institute group around David Liu, the scientist who invented base editing technology itself. Liu has been publicly responsible about the applications of his invention; how he positions himself publicly as commercial pressure mounts will be a critical signal for the whole field.
Equally important in the medium term is the question of international regulatory coordination — or the absence of it. Right now, no internationally binding agreement on human germline editing exists. WHO published a genome editing governance framework in 2021, but it is purely advisory. I estimate roughly 55% probability that, by 2027, a UN or WHO-level process to negotiate a binding convention will have formally begun. But even if negotiations start promptly, a treaty with real enforcement mechanisms will take a minimum of five additional years to finalize and ratify. That gap — from research milestone to enforceable law — is where regulatory arbitrage will flourish. Clinics will establish themselves in jurisdictions with limited oversight, offering high-cost services to the global affluent. The stem cell tourism of the 2000s is the relevant precedent, and embryo editing tourism is more commercially attractive by orders of magnitude.
Looking further ahead, the two-to-five year horizon presents three distinct scenarios. The optimistic scenario, which I assign roughly 20% probability, involves the international community moving with unusual speed: a governance framework is established that permits embryo editing strictly for severe single-gene disorders under rigorous oversight, with independent verification and international data sharing required as conditions of authorization. Under this scenario, the first authorized clinical research programs for conditions like sickle cell disease and cystic fibrosis could begin around 2029 or 2030. The public health impact would be profound — sickle cell disease affects approximately 300,000 newborns annually, disproportionately in sub-Saharan Africa, where it remains a leading cause of under-five mortality. The reason I assign only 20% to this outcome is not technical infeasibility but historical reality: international consensus on topics intersecting deeply held religious values and enormous commercial interests has consistently proven extraordinarily slow. Nuclear nonproliferation, climate agreements, pandemic preparedness — the track record is not encouraging.
The baseline scenario, at roughly 55% probability, is one of suspended animation: major regulatory jurisdictions maintain current prohibitions on clinical germline editing while permitting continued laboratory research, pushing clinical questions past 2030. During this window, data accumulates from animal studies — particularly non-human primate models — and scientific understanding of base editing safety, mosaicism, and long-term developmental effects gradually improves. The problem is that technology keeps advancing and commercial pressure keeps building during this same window, steadily widening the gap between technical possibility and legal permission. I estimate roughly 35% probability that by 2028 at least one unauthorized germline editing birth will be reported from a low-oversight jurisdiction — a second He Jiankui moment, but with technology that is demonstrably more refined, making continued prohibition harder to defend on purely technical-safety grounds than it was in 2018.
The pessimistic scenario, at roughly 25% probability, is the one that concerns me most: unregulated commercialization advances faster than law, and a de facto market for premium embryo editing services establishes itself in regulatory grey zones. Initial pricing in the $500,000 to $1 million range places this within reach of the top one to five percent of global income earners — the same demographic that purchases Manhattan real estate as a portfolio hedge. As technical costs decline over five to seven years, the accessible population widens, but regulatory and equity frameworks still don't exist. The most sobering feature of this scenario is intergenerational compounding. A family that uses this technology in 2028 transmits optimized genetic sequences to every subsequent generation, automatically, without further cost or intervention. Against current global wealth distribution — where the top 10% control roughly 76% of all assets — adding a biological multiplier to that concentration produces a form of stratification that no redistribution mechanism in our current political toolkit can address.
I should be honest about the ways this analysis could be wrong. Mosaicism may turn out to be a more fundamental technical barrier than current optimism implies, delaying safe clinical application by a decade or more beyond what today's efficiency numbers suggest. In vitro results do not automatically predict what happens during actual embryonic development after implantation, and the gap between laboratory efficiency and developmental biology has surprised researchers repeatedly in the history of genetics. Public moral opposition could prove more durable and politically consequential than technological optimism typically accounts for — the European response to GMOs, sustained and politically effective despite scientific consensus on safety, is the most relevant precedent. Populations can and do maintain categorical prohibitions on technologies associated with "playing God," and that moral intuition should not be easily dismissed as irrational.
The most practical thing I can offer: watch the regulatory calendars. Watch what the UK's HFEA decides in its response to Egli's results. Watch whether the U.S. Congress allows the germline editing appropriations rider to lapse or makes it permanent law. Watch where Beam Therapeutics and the Broad Institute publicly position themselves on clinical application, because their choices will signal which direction commercial momentum is headed. If you have any capacity to participate in public bioethics consultations — national ethics boards, academic forums, policy comment periods — use it. This is not a decision that should be made by scientists, investors, and regulators in isolation from the people whose children will live in the world those decisions create. The question of whether genetic advantage becomes the next frontier of inherited privilege is one the entire public has a stake in answering, and it is being decided right now.
Sources / References
- Precise genome editing in human embryos — bioRxiv
- Precise genome editing of human embryos triggers praise and alarm — Nature
- Report of Gene-Edited Human Embryos Sparks Worries — Scientific American
- Precise Gene Editing in Early Human Embryos Reignites the Designer Baby Debate — Singularity Hub
- Latest Gene Editing of Human Embryos Could Open the Floodgates — Futurism
- Base Editing in Human Embryos — Chemical & Engineering News
- ASGCT·ISCT, 인간 생식세포 편집 10년 금지 촉구 — 약사공론